Introduction: Blood cancer survivors are at increased risk for medical complications. Methods: Our questionnaire-based study involved 1,551 blood cancer survivors with a ≥3-year interval since the last intense treatment. Its goal was to quantify health-related complications during follow-up and assess their impact on the patients’ lives. Results: A total of 20.4% of the responding survivors reported a disease relapse, most often in indolent lymphomas. Second primary malignancies occurred in 14.1%, primarily in lymphoma and allogeneic transplantation survivors. The most frequent malignancy was basal cell carcinoma of the skin, but myeloid malignancies, melanoma, bladder, head-and-neck, and thyroid cancer also appeared disproportionately frequent. An increased infection rate was reported by 43.7%, most often after allogeneic transplantation. New cardiovascular diseases were reported by 30.2%, with a high rate of thromboembolic events in multiple myeloma (MM) and myeloproliferative diseases. Polyneuropathies were reported by 39.1%, most often by survivors with a history of MM or aggressive lymphoma. Disease relapse was perceived as the highest burden, followed by second primary malignancy, increased infection frequency, and polyneuropathy. In each area investigated, the range of perceived severities was wide. Conclusions: Health-related complications are frequent during blood cancer follow-up, with significant repercussions on the patients’ lives.

1.
Damlaj
M
,
El Fakih
R
,
Hashmi
SK
.
Evolution of survivorship in lymphoma, myeloma and leukemia: metamorphosis of the field into long term follow-up care
.
Blood Rev
.
2019
;
33
:
63
73
. .
2.
Saunders
IM
,
Tan
M
,
Koura
D
,
Young
R
.
Long-term follow-up of hematopoietic stem cell transplant survivors: a focus on screening, monitoring, and therapeutics
.
Pharmacotherapy
.
2020
;
40
(
8
):
808
41
. .
3.
Yanada
M
,
Garcia-Manero
G
,
Borthakur
G
,
Ravandi
F
,
Kantarjian
H
,
Estey
E
.
Potential cure of acute myeloid leukemia: analysis of 1069 consecutive patients in first complete remission
.
Cancer
.
2007
;
110
(
12
):
2756
60
. .
4.
Maurer
MJ
,
Ghesquières
H
,
Jais
JP
,
Witzig
TE
,
Haioun
C
,
Thompson
CA
, et al
.
Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy
.
J Clin Oncol
.
2014
;
32
(
10
):
1066
73
. .
5.
Zuanelli Brambilla
C
,
Lobaugh
SM
,
Ruiz
JD
,
Dahi
PB
,
Goldberg
AD
,
Young
JW
, et al
.
Relapse after allogeneic stem cell transplantation of acute myelogenous leukemia and myelodysplastic syndrome and the importance of second cellular therapy
.
Transplant Cell Ther
.
2021
;
27
(
9
):
771.e1
771.e10
. .
6.
Islam
B
,
Lustberg
M
,
Staff
NP
,
Kolb
N
,
Alberti
P
,
Argyriou
AA
.
Vinca alkaloids, thalidomide and eribulin-induced peripheral neurotoxicity: from pathogenesis to treatment
.
J Peripher Nerv Syst
.
2019
;
24
(
Suppl 2
):
S63
73
. .
7.
Li
T
,
Timmins
HC
,
King
T
,
Kiernan
MC
,
Goldstein
D
,
Park
SB
.
Characteristics and risk factors of bortezomib induced peripheral neuropathy: a systematic review of phase III trials
.
Hematol Oncol
.
2020
;
38
(
3
):
229
43
. .
8.
Shree
T
,
Li
Q
,
Glaser
SL
,
Brunson
A
,
Maecker
HT
,
Haile
RW
, et al
.
Impaired immune health in survivors of diffuse large B-cell lymphoma
.
J Clin Oncol
.
2020
;
38
(
15
):
1664
75
. .
9.
Pirani
M
,
Marcheselli
R
,
Marcheselli
L
,
Bari
A
,
Federico
M
,
Sacchi
S
.
Risk for second malignancies in non-Hodgkin’s lymphoma survivors: a meta-analysis
.
Ann Oncol
.
2011
;
22
(
8
):
1845
58
. .
10.
Danylesko
I
,
Shimoni
A
.
Second malignancies after hematopoietic stem cell transplantation
.
Curr Treat Options Oncol
.
2018
;
19
(
2
):
9
. .
11.
Chattopadhyay
S
,
Zheng
G
,
Sud
A
,
Yu
H
,
Sundquist
K
,
Sundquist
J
, et al
.
Risk of second primary cancer following myeloid neoplasia and risk of myeloid neoplasia as second primary cancer: a nationwide, observational follow up study in Sweden
.
Lancet Haematol
.
2018
;
5
(
8
):
e368
77
. .
12.
Perpinia
AS
,
Kadoglou
N
,
Vardaka
M
,
Gkortzolidis
G
,
Karavidas
A
,
Marinakis
T
, et al
.
Pharmaceutical prevention and management of cardiotoxicity in hematological malignancies
.
Pharmaceuticals
.
2022
;
15
(
8
):
1007
. .
13.
Baum
J
,
Lax
H
,
Lehmann
N
,
Merkel-Jens
A
,
Beelen
DW
,
Jöckel
KH
, et al
.
Patient-reported patterns of follow-up care in the ‚Aftercare in Blood Cancer Survivors’ (ABC) study
.
J Cancer Res Clin Oncol
.
2023
;
149
(
12
):
10531
42
. .
14.
Molassiotis
A
,
Wilson
B
,
Blair
S
,
Howe
T
,
Cavet
J
.
Unmet supportive care needs, psychological well-being and quality of life in patients living with multiple myeloma and their partners
.
Psychooncology
.
2011
;
20
(
1
):
88
97
. .
15.
Hultcrantz
M
,
Kristinsson
SY
,
Andersson
TM
,
Landgren
O
,
Eloranta
S
,
Derolf
AR
, et al
.
Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study
.
J Clin Oncol
.
2012
;
30
(
24
):
2995
3001
. .
16.
Hughes
TP
,
Shanmuganathan
N
.
Management of TKI-resistant chronic phase CML
.
Hematol Am Soc Hematol Educ Program
.
2022
;
2022
(
1
):
129
37
. .
17.
Dührsen
U
.
Therapy-induced leukemia – an underestimated complication of antineoplastic chemotherapy
.
Zentralbl Gynakol
.
2005
;
127
(
04
):
235
41
. .
18.
Iglesias
ML
,
Schmidt
A
,
Ghuzlan
AA
,
Lacroix
L
,
Vathaire
F
,
Chevillard
S
, et al
.
Radiation exposure and thyroid cancer: a review
.
Arch Endocrinol Metab
.
2017
;
61
(
2
):
180
7
. .
19.
Hemminki
K
,
Jiang
Y
,
Steineck
G
.
Skin cancer and non-Hodgkin’s lymphoma as second malignancies. markers of impaired immune function
.
Eur J Cancer
.
2003
;
39
(
2
):
223
9
. .
20.
Herr
MM
,
Schonfeld
SJ
,
Dores
GM
,
Withrow
DR
,
Tucker
MA
,
Curtis
RE
, et al
.
Mutual risks of cutaneous melanoma and specific lymphoid neoplasms: second cancer occurrence and survival
.
J Natl Cancer Inst
.
2018
;
110
(
11
):
1248
58
. .
21.
Cantisani
C
,
Kiss
N
,
Naqeshbandi
AF
,
Tosti
G
,
Tofani
S
,
Cartoni
C
, et al
.
Nonmelanoma skin cancer associated with Hydroxyurea treatment: overview of the literature and our own experience
.
Dermatol Ther
.
2019
;
32
(
5
):
e13043
. .
22.
Parnes
R
,
Safai
B
,
Myskowski
PL
.
Basal cell carcinomas and lymphoma: biologic behavior and associated factors in sixty-three patients
.
J Am Acad Dermatol
.
1988
;
19
(
6
):
1017
23
. .
23.
Schwartz
JL
,
Kopecky
KJ
,
Mathes
RW
,
Leisenring
WM
,
Friedman
DL
,
Deeg
HJ
.
Basal cell skin cancer after total body irradiation and hematopoietic cell transplantation
.
Radiat Res
.
2009
;
171
(
2
):
155
63
. .
24.
Travis
LB
,
Curtis
RE
,
Glimelius
B
,
Holowaty
EJ
,
Van Leeuwen
FE
,
Lynch
CF
, et al
.
Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin’s lymphoma
.
J Natl Cancer Inst
.
1995
;
87
(
7
):
524
30
. .
25.
Douglas
CM
,
Jethwa
AR
,
Hasan
W
,
Liu
A
,
Gilbert
R
,
Goldstein
D
, et al
.
Long-term survival of head and neck squamous cell carcinoma after bone marrow transplant
.
Head Neck
.
2020
;
42
(
11
):
3389
95
. .
26.
Royle
JS
,
Baade
P
,
Joske
D
,
Fritschi
L
.
Risk of second cancer after lymphohematopoietic neoplasm
.
Int J Cancer
.
2011
;
129
(
4
):
910
9
. .
27.
Morton
LM
,
Onel
K
,
Curtis
RE
,
Hungate
EA
,
Armstrong
GT
.
The rising incidence of second cancers: patterns of occurrence and identification of risk factors for children and adults
.
Am Soc Clin Oncol Educ Book
.
2014
;
2014
(
34
):
e57
67
. .
28.
Brabrand
M
,
Frederiksen
H
.
Risks of solid and lymphoid malignancies in patients with myeloproliferative neoplasms: clinical implications
.
Cancers
.
2020
;
12
(
10
):
3061
. .
29.
Van der Straten
L
,
Levin
MD
,
Dinnessen
MAW
,
Visser
O
,
Posthuma
EFM
,
Doorduijn
JK
, et al
.
Risk of second primary malignancies in patients with chronic lymphocytic leukemia: a population-based study in The Netherlands, 1989-2019
.
Blood Cancer J
.
2023
;
13
(
1
):
15
. .
30.
National Opinion Research Center (NORC) at the University of Chicago
.
Percent of cancers detected by screening
[cited 2023 Aug 15]. Available from: https://cancerdetection.norc.org.
31.
Baum
J
,
Lax
H
,
Lehmann
N
,
Merkel-Jens
A
,
Beelen
DW
,
Jöckel
KH
, et al
.
Preventive health care in blood cancer survivors: results from the ABC study
.
J Cancer Res Clin Oncol
.
2023
;
149
(
13
):
11531
40
. .
32.
Howlader
N
,
Mariotto
AB
,
Besson
C
,
Suneja
G
,
Robien
K
,
Younes
N
, et al
.
Cancer-specific mortality, cure fraction, and noncancer causes of death among diffuse large B-cell lymphoma patients in the immunochemotherapy era
.
Cancer
.
2017
;
123
(
17
):
3326
34
. .
33.
Moser
EC
,
Noordijk
EM
,
van Leeuwen
FE
,
Le Cessie
S
,
Baars
JW
,
Thomas
J
, et al
.
Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin lymphoma
.
Blood
.
2006
;
107
(
7
):
2912
9
. .
34.
Bhatia
S
,
Armenian
SH
,
Landier
W
.
How I monitor long-term and late effects after blood or marrow transplantation
.
Blood
.
2017
;
130
(
11
):
1302
14
. .
35.
Chung
R
,
Tyebally
S
,
Chen
D
,
Kapil
V
,
Walker
JM
,
Addison
D
, et al
.
Hypertensive cardiotoxicity in cancer treatment – systematic analysis of adjunct, conventional chemotherapy, and novel therapies – epidemiology, incidence, and pathophysiology
.
J Clin Med
.
2020
;
9
(
10
):
3346
. .
36.
Musallam
KM
,
Dahdaleh
FS
,
Shamseddine
AI
,
Taher
AT
.
Incidence and prophylaxis of venous thromboembolic events in multiple myeloma patients receiving immunomodulatory therapy
.
Thromb Res
.
2009
;
123
(
5
):
679
86
. .
37.
Moslehi
JJ
,
Deininger
M
.
Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia
.
J Clin Oncol
.
2015
;
33
(
35
):
4210
8
. .
38.
Textor
LH
,
Hedrick
J
.
The lived experience of peripheral neuropathy after solid organ transplant
.
Prog Transplant
.
2012
;
22
(
3
):
271
9
. .
39.
Sullivan
GM
,
Artino
AR
Jr
.
Analyzing and interpreting data from likert-type scales
.
J Grad Med Educ
.
2013
;
5
(
4
):
541
2
. .
You do not currently have access to this content.